BidaskClub upgraded shares of ProQR Therapeutics (NASDAQ:PRQR) from a sell rating to a hold rating in a research note issued to investors on Tuesday morning.
A number of other research analysts have also issued reports on the stock. HC Wainwright reiterated a buy rating and issued a $20.00 target price on shares of ProQR Therapeutics in a research note on Thursday, February 28th. Cantor Fitzgerald set a $40.00 target price on shares of ProQR Therapeutics and gave the company a buy rating in a research note on Tuesday, January 29th. Zacks Investment Research upgraded shares of ProQR Therapeutics from a hold rating to a strong-buy rating and set a $20.00 target price on the stock in a research note on Wednesday, January 9th. Chardan Capital reiterated a buy rating and issued a $21.00 target price on shares of ProQR Therapeutics in a research note on Monday, January 7th. Finally, Royal Bank of Canada began coverage on shares of ProQR Therapeutics in a research note on Wednesday, December 19th. They issued an outperform rating on the stock. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus target price of $28.67.
Shares of PRQR opened at $15.03 on Tuesday. ProQR Therapeutics has a 12 month low of $2.90 and a 12 month high of $24.00. The firm has a market cap of $581.96 million, a PE ratio of -11.65 and a beta of 0.63. The company has a current ratio of 13.28, a quick ratio of 11.39 and a debt-to-equity ratio of 0.10.
About ProQR Therapeutics
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.
Recommended Story: Why are percentage decliners important?
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.